Correction: Serum 25-Hydroxyvitamin D Concentrations ≥40 ng/ml Are Associated with >65% Lower Cancer Risk: Pooled Analysis of Randomized Trial and Prospective Cohort Study.

Correction: Serum 25-Hydroxyvitamin D Concentrations ≥40 ng/ml Are Associated with >65% Lower Cancer Risk: Pooled Analysis of Randomized Trial and Prospective Cohort Study.

[This corrects the article DOI: 10.1371/journal.pone.0152441.].

Bibliographic Details
Main Authors:	Sharon L McDonnell, Carole Baggerly, Christine B French, Leo L Baggerly, Cedric F Garland, Edward D Gorham, Joan M Lappe, Robert P Heaney
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2018-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC6047822?pdf=render

Similar Items

Serum 25-Hydroxyvitamin D Concentrations ≥40 ng/ml Are Associated with >65% Lower Cancer Risk: Pooled Analysis of Randomized Trial and Prospective Cohort Study.
by: Sharon L McDonnell, et al.
Published: (2016-01-01)

Breast cancer risk markedly lower with serum 25-hydroxyvitamin D concentrations ≥60 vs <20 ng/ml (150 vs 50 nmol/L): Pooled analysis of two randomized trials and a prospective cohort.
by: Sharon L McDonnell, et al.
Published: (2018-01-01)

Maternal 25(OH)D concentrations ≥40 ng/mL associated with 60% lower preterm birth risk among general obstetrical patients at an urban medical center.
by: Sharon L McDonnell, et al.
Published: (2017-01-01)

25-Hydroxyvitamin D variability within-person due to diurnal rhythm and illness: a case report
by: Christine B. French, et al.
Published: (2019-02-01)

The likelihood of having serum level of PSA of ≥4.0 ng/mL and ≥10.0 ng/mL in non-obese and obese Nigerian men with LUTS
by: Patrick Temi Adegun, et al.
Published: (2015-07-01)

Vitamin D and omega-3 field study on progression of type 1 diabetes
by: C. Ricordi, et al.
Published: (2019-08-01)

Expression of Concern: Vitamin D sufficiency, a serum 25-hydroxyvitamin D at least 30 ng/mL reduced risk for adverse clinical outcomes in patients with COVID-19 infection.
by: PLOS ONE Editors
Published: (2020-01-01)

Combining clinical parameters and multiparametric magnetic resonance imaging to stratify biopsy-naïve men for an optimum diagnostic strategy with prostate-specific antigen 4 ng ml−1 to 10 ng ml−1
by: Chi-Chen Zhang, et al.
Published: (2023-01-01)

Effect of Antibiotic on Men with Raised Prostatic-Specific Antigen (4-10 ng/ml)
by: Abdulsattar J. Ali, et al.
Published: (2020-12-01)

Histopathological findings in extended prostate biopsy with PSA ≤ 4 ng/mL
by: Katia R. Leite, et al.
Published: (2008-06-01)

Comparison of Pathology and Prevalence of Prostate Cancer in Patients with PSA between 4-10 ng/ml
by: A Tabibi, et al.
Published: (2008-01-01)

Pathological characteristics and predictive factors of prostate biopsy in patients with serum PSA levels between 0 and 4.0 ng/ml
by: Rui Su, et al.
Published: (2022-07-01)

Strategy for prostate cancer patients with low prostate specific antigen level (2.5 to 4.0 ng/ mL)
by: J.H. Chung, et al.
Published: (2020-07-01)

PSA density improves the rate of prostate cancer detection in Chinese men with a PSA between 2.5-10.0 ng ml -1 and 10.1-20.0 ng ml -1 : a multicenter study
by: Yu-Rong Lin, et al.
Published: (2015-06-01)

The Chances of Subsequent Cancer Detection in Patients with a PSA > 20 ng/ml and an Initial Negative Biopsy
by: Nadeem Shaida, et al.
Published: (2009-01-01)

Free PSA estimation substituted by calculation where total PSA value is up to 4 ng/ml
by: M Dhumne, et al.
Published: (2006-01-01)

Stromal Tumor of Uncertain Malignant Potential (STUMP) With PSA >500 ng/ml: A Case Report
by: Michael H. Johnson, et al.
Published: (2015-09-01)

PSA levels of 4.0 - 10 ng/ml and negative digital rectal examination: antibiotic therapy versus immediate prostate biopsy
by: Avraham Shtricker, et al.
Published: (2009-10-01)

Correlation of Serum Androgens and Pituitary Hormone Levels with Serum PSA Less Than 2.5 NG/ML
by: Mustafa Sofikerim, et al.
Published: (2007-01-01)

Early detection of Prostate Cancer with Prostate Specific Antigen > 4 ng/ml : A Multivariate Logistic Regression
by: Prahara Yuri, et al.
Published: (2015-04-01)

Bias, Randomization, and Ovarian Proteomic Data: A Reply to
by: Keith A. Baggerly, Kevin R. Coombes, and Jeffrey S. Morris
Published: (2005-01-01)

Predictive factors of prostate cancer diagnosis with PSA 4.0–10.0 ng/ml in a multi-ethnic Asian population, Malaysia
by: Yii, Raymond Shi Liang, et al.
Published: (2020)

Low antimüllerian hormone (<1.2 ng/ml) does not impact oocyte quality and IVF/ICSI outcomes in women ≤40 years old
by: Ming-Ju Wang, et al.
Published: (2025-03-01)

Predictive factors of prostate cancer diagnosis with PSA 4.0–10.0 ng/ml in a multi-ethnic Asian population, Malaysia
by: Raymond Shi Liang Yii, et al.
Published: (2020-01-01)

Effect of Vitamin D<sub>3</sub> Supplementation vs. Dietary–Hygienic Measures on SARS-CoV-2 Infection Rates in Hospital Workers with 25-Hydroxyvitamin D3 [25(OH)D3] Levels ≥20 ng/mL
by: Maria Elena Romero-Ibarguengoitia, et al.
Published: (2023-01-01)

Voided Urine Sample in the Diagnosis of Prostate Cancer in Patients with Serum PSA Ranging between 2.6 to 10 ng/mL
by: Shridhar C. Ghagane, et al.
Published: (2023-10-01)

Integration of PSAd and multiparametric MRI to forecast biopsy outcomes in biopsy-naïve patients with PSA 4~20 ng/ml
by: Lei Ren, et al.
Published: (2024-07-01)

Prognosis of patients with prostate cancer and middle range prostate - specific antigen levels of 20 – 100 ng / mL
by: Hiroaki Iwamoto, et al.

Surface Adjustment of Reverse Phase Protein Arrays using Positive Control Spots
by: E. Shannon Neeley, et al.
Published: (2012-04-01)

Surface Adjustment of Reverse Phase Protein Arrays using Positive Control Spots
by: E. Shannon Neeley, et al.
Published: (2012-01-01)

Study on mechanical efficiency of 65 ml/r fuel pump and its piston optimization
by: Yang Ding, et al.
Published: (2023-09-01)

The research of the application of a new urinary biomarker PCA-M of prostate cancer (PSA from 4 to 20 ng/ml)
by: Zhiyu Zhang, et al.
Published: (2022-12-01)

Overcoming Infections Including COVID-19, by Maintaining Circulating 25(OH)D Concentrations Above 50 ng/mL
by: Wimalawansa SJ
Published: (2022-12-01)

DCE-MRI and DWI can differentiate benign from malignant prostate tumors when serum PSA is ≥10 ng/ml
by: Hongmei Sun, et al.
Published: (2022-12-01)

Serum and tissue monocyte differentiation in PSA value 4–10 ng/mL prostate cancer and benign prostatic hyperplasia
by: Yuanyuan Guo, et al.
Published: (2018-11-01)

DIAGNOSIS OF PROSTATIC NEOPLASM LATER TO ANTIBIOTIC TREATMENT IN PATIENTS WITH PROSTATE-SPECIFIC ANTIGEN BETWEEN 4 AND 10 ng/ml (IN SPANISH)
by: Infantes-Burgos Ronald Javier, et al.
Published: (2014-01-01)

Patients with COVID-19 pneumonia with 25(OH)D levels lower than 12 ng/ml are at increased risk of death
by: Juraj Smaha, et al.
Published: (2022-03-01)

Serum levels of unconjugated bisphenol A are below 0.2 ng/ml in Swedish nursing women when contamination is minimized
by: Irina Gyllenhammar, et al.
Published: (2014-03-01)

Sensitive and quantitative universal Pyrosequencing™ methylation analysis of CpG sites
by: S. Colella, et al.
Published: (2003-07-01)

Protein and phosphoprotein levels in glioma and adenocarcinoma cell lines grown in normoxia and hypoxia in monolayer and three-dimensional cultures
by: Levin Victor A, et al.
Published: (2012-01-01)